#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Dupuytren's contracture Henoch-Schonlein purpura nephritis Transitional cell cancer of the renal pelvis and ureter Arterial tortuosity syndrome Hyperadrenocorticism Emphysema Pituitary-dependent Cushing's syndrome Fibrosarcoma metastatic Behcet's syndrome Exudative retinopathy Thrombotic thrombocytopenic purpura Oropharyngeal cancer recurrent Glomerulonephritis Primary immunodeficiency syndrome Oesophageal adenocarcinoma stage III More trials…

    Learn about Rare Diseases

    Sarcoma – Trials in Disease Cystic fibrosis lung – Trials in Disease Idiopathic pulmonary fibrosis – Trials in Disease Nephrotic syndrome – Trials in Disease Leukoencephalopathy – Treatment Rhabdoid tumour – Diagnostics Krabbe’s disease – Life with Disease Rett syndrome – Trials in Disease Glomerulonephritis membranous – Treatment Osteosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rmc-6291 Pentixafor Gallium Ga-68 Rifamycin Sodium Oxybuprocaine ADCE-D01 Trientine Dihydrochloride Ferrous Sulfate Abacavir Sulfate Panobinostat Troriluzole Sorafenib Glutenin Vinorelbine Tartrate Marstacimab Star-0215 S-241656 Ginisortamab Metoprolol Succinate Soya Oil, Purified Protease More therapies…

    Learn about Your Condition

    Renal cancer metastatic Arteriosclerosis Injury Plasma cell leukaemia Colon cancer Acute cardiac event Fracture infection Corneal graft rejection Monkeypox Endocrine disorder Renal cancer stage IV Leber's congenital amaurosis Pharyngeal cancer stage II Vasoplegia syndrome HER2 protein overexpression More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Noe LGA Gesundheit Region Mitte GmbH

Noe LGA Gesundheit Region Mitte GmbH

Alter Ziegelweg 10, St. Poelten, 3430, Austria

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer stage I
    • Breast cancer male
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Cisplatin
    Austria Belgium France Germany Ireland Spain

  • Study of AB-1002 gene therapy given through coronary arteries in adults with severe (NYHA Class III) heart failure caused by non-ischemic cardiomyopathy

    Not recruiting

    2 1
    Investigated Drugs:
    • Ab-1002
    Austria Belgium Bulgaria Germany Hungary The Netherlands +3

  • Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Fianlimab
    • Cemiplimab
    Austria France Germany Greece Ireland Italy +2

  • Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Betamethasone Sodium Phosphate
    • Bortezomib
    • Isatuximab
    Austria Germany

  • Study of Rituximab, Polatuzumab Vedotin, and Glofitamab for Untreated Aggressive B-cell Lymphoma in Patients Over 60 Not Eligible for Full R-CHOP

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    Investigated Drugs:
    • Polatuzumab Vedotin
    • Glofitamab
    • Obinutuzumab
    Austria Germany

  • Study on Baxdrostat for Reducing Blood Pressure in Patients with Uncontrolled or Resistant Hypertension

    Not recruiting

    3 1
    Investigated Diseases:
    • Hypertension
    Investigated Drugs:
    • Baxdrostat
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study on the Safety of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Lenalidomide
    • Tafasitamab
    Austria Czechia Italy Poland Spain

  • Study on the Effectiveness and Safety of Rosnilimab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Rosnilimab
    Austria Bulgaria Croatia France Germany Italy +4

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicle centre lymphoma follicular grade I II – III refractory
    Investigated Drugs:
    • Epcoritamab
    • Lenalidomide
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +8
Previous Page
1 … 5 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!